Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Free Cash Flow for 6 consecutive years, with $29.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 163.83% to $29.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$109.1 million through Dec 2025, up 19.25% year-over-year, with the annual reading at -$109.1 million for FY2025, 19.25% up from the prior year.
  • Free Cash Flow for Q4 2025 was $29.2 million at 4D Molecular Therapeutics, up from -$46.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was $29.2 million in Q4 2025, with the low at -$47.9 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$24.1 million, with a median of -$25.3 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 9743.19% in 2024, then soared 163.83% in 2025.
  • Over 5 years, Free Cash Flow stood at -$20.0 million in 2021, then decreased by 14.15% to -$22.9 million in 2022, then fell by 18.47% to -$27.1 million in 2023, then plummeted by 68.7% to -$45.7 million in 2024, then skyrocketed by 163.83% to $29.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $29.2 million, -$46.4 million, and -$43.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.